uniQure (QURE) Total Non-Current Liabilities (2015 - 2026)
uniQure (QURE) posted quarterly Total Non-Current Liabilities of $577.7 million for Q2 2026, up 5.43% year-over-year from $548.0 million in Q2 2025, and up 1.32% quarter-over-quarter from $570.2 million in Q1 2026.
uniQure (QURE) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
uniQure's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $577.7 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 5.43% year-over-year to $577.7 million; the TTM figure through Jun 2026 stood at $577.7 million (up 5.43% YoY), while the FY2025 annual figure was $563.1 million, up 7.62% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $577.7 million, up from $570.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $577.7 million in Q2 2026, with the low at $151.9 million in Q1 2023.
- The 5-year median for Total Non-Current Liabilities is $534.8 million (2023), against an average of $439.2 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities fell 13.36% in 2022, then surged 268.55% in 2024.
- uniQure's Total Non-Current Liabilities stood at $153.0 million in 2022, then surged by 259.62% to $550.3 million in 2023, then declined by 4.93% to $523.2 million in 2024, then gained by 7.62% to $563.1 million in 2025, then rose by 2.6% to $577.7 million in 2026.
- Business Quant data shows QURE's Total Non-Current Liabilities at $577.7 million in Q2 2026, $570.2 million in Q1 2026, and $563.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | uniQure | 3.37 Bn | 3.37 Bn | 5.49 Mn | 577.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 577.71 Mn |
| Mar 31, 2026 | 570.17 Mn |
| Dec 31, 2025 | 563.09 Mn |
| Sep 30, 2025 | 559.00 Mn |
| Jun 30, 2025 | 547.96 Mn |
| Mar 31, 2025 | 535.41 Mn |
| Dec 31, 2024 | 523.24 Mn |
| Sep 30, 2024 | 518.71 Mn |
| Jun 30, 2024 | 553.27 Mn |
| Mar 31, 2024 | 559.82 Mn |
| Dec 31, 2023 | 550.34 Mn |
| Sep 30, 2023 | 534.16 Mn |
| Jun 30, 2023 | 521.09 Mn |
| Mar 31, 2023 | 151.90 Mn |
| Dec 31, 2022 | 153.04 Mn |
| Sep 30, 2022 | 153.09 Mn |
| Jun 30, 2022 | 166.46 Mn |
| Mar 31, 2022 | 166.45 Mn |
| Dec 31, 2021 | 176.64 Mn |
| Sep 30, 2021 | 141.95 Mn |